文献速递泌尿生殖与妇科肿瘤放疗

挽救性放疗对PSMA-PET阴性的生化复发患者有效:一项回顾性研究结果

Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
PubMed 文献 · Radiother Oncol · 2023-05-03

这项回顾性多中心分析纳入341例根治性前列腺切除术后生化复发、PSMA-PET未见相关病灶且未接受ADT的患者,评估前列腺窝挽救性放疗的生化无进展生存。中位随访28.0个月,PET阴性者3年BPFS为71.6%,局部PET阳性者为80.8%,多因素分析无显著差异。结果支持EAU关于PET阴性患者检测到生化复发后及时启动挽救性放疗的推荐。

要点

  • PET阴性者3年BPFS为71.6%,局部PET阳性者为80.8%,多因素分析无显著差异。
  • PET阴性者多因素分析中仅年龄(HR 1.096)和PSA倍增时间(HR 0.339)与BPFS显著相关。
  • 结果支持EAU推荐:PET阴性患者检测到生化复发后应及时启动挽救性放疗。

核心结论

  • 多因素分析显示局部PET阳性与PET阴性病例的生化无进展生存无显著差异。
  • 结果支持当前EAU关于PET阴性患者检测到生化复发后及时启动挽救性放疗的推荐。

研究设计与样本

  • 回顾性、多中心分析,纳入根治性前列腺切除术后因生化复发转诊行PSMA-PET的1222例患者。
  • 排除病理性淋巴结转移、PSA持续存在、远处或淋巴结转移、淋巴结照射及雄激素剥夺治疗(ADT)后,最终队列为341例患者。
  • 主要研究终点为生化无进展生存(BPFS)。

主要发现

  • 中位随访28.0个月。
  • 3年BPFS在PET阴性病例为71.6%,在局部PET阳性病例为80.8%。
  • 该差异在单因素分析中显著(p=0.019),但在多因素分析中不显著(p=0.366,HR 1.46,95%CI 0.64-3.32)。
  • PET阴性病例的3年BPFS在单因素分析中受年龄(p=0.005)、初始pT3/4(p<0.001)、病理评分(ISUP)≥3(p=0.026)及前列腺窝剂量>70 Gy(p=0.027)显著影响。
  • 多因素分析中仅年龄(HR 1.096,95%CI 1.023-1.175,p=0.009)和PSA倍增时间(HR 0.339,95%CI 0.139-0.826,p=0.017)仍显著。

关键数值与推荐

  • PET阴性病例3年BPFS为71.6%,局部PET阳性病例为80.8%。
  • 单因素分析p=0.019;多因素分析p=0.366,HR 1.46,95%CI 0.64-3.32。
  • PET阴性病例多因素分析:年龄HR 1.096(95%CI 1.023-1.175,p=0.009);PSA倍增时间HR 0.339(95%CI 0.139-0.826,p=0.017)。

临床怎么用

  • 作者结论支持当前EAU推荐:PET阴性患者检测到生化复发后应及时启动挽救性放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: The present study aimed to assess whether SRT to the prostatic fossa should be initiated in a timely manner after detecting biochemical recurrence (BR) in patients with prostate cancer, when no correlate was identified with prostate-specific membrane antigen positron emission tomography (PSMA-PET). MATERIALS AND METHODS: This retrospective, multicenter analysis included 1222 patients referred for PSMA-PET after a radical prostatectomy due to BR. Exclusion criteria were: pathological lymph node metastases, prostate-specific antigen (PSA) persistence, distant or lymph node metastases, nodal irradiation, and androgen deprivation therapy (ADT). This led to a cohort of 341 patients. Biochemical progression-free survival (BPFS) was the primary study endpoint. RESULTS: The median follow-up was 28.0 months. The 3-year BPFS was 71.6% in PET-negative cases and 80.8% in locally PET-positive cases. This difference was significant in univariate (p = 0.019), but not multivariate analyses (p = 0.366, HR: 1.46, 95%CI: 0.64-3.32). The 3-year BPFS in PET-negative cases was significantly influenced by age (p = 0.005), initial pT3/4 (p < 0.001), pathology scores (ISUP) ≥ 3 (p = 0.026), and doses to fossa > 70 Gy (p = 0.027) in univariate analyses. In multivariate analyses, only age (HR: 1.096, 95%CI: 1.023-1.175, p = 0.009) and PSA-doubling time (HR: 0.339, 95%CI: 0.139-0.826, p = 0.017) remained significant. CONCLUSION: To our best knowledge, this study provided the largest SRT analysis in patients without ADT that were lymph node-negative on PSMA-PET. A multivariate analysis showed no significant difference in BPFS between locally PET-positive and PET-negative cases. These results supported the current EAU recommendation to initiate SRT in a timely manner after detecting BR in PET negative patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Scharl S, Zamboglou C, Strouthos I, et al. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study. Radiother Oncol. 2023. PMID: 37146766. doi:10.1016/j.radonc.2023.109678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。